Bioventus
- Market cap
- 872.26M
- P/E (TTM)i
- 16.37
- P/Bi
- 3.82
- EPSi
- 0.33
- Div yieldi
- 0.00%
- 52W posi
- 67%
Anonymous reader poll. Unscientific, not investment advice.
About Bioventus
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.
- Founded
- 2015
- CEO
- Mr. Robert E. Claypoole
- Employees
- 930
- Headquarters
- Durham, North Carolina, United States of America
- Fiscal year end
- 12-31
- Website
- bioventus.com
Company profile
- Exchange
- US
- Symbol
- BVS
- Market-cap rank
- #3345
- Listing date
- 2021-02-11
- Market cap
- 872.26M
- Float cap
- 427.45M
- Shares out
- 68.31M
- Float shares
- 33.47M
Sectors & themes
Quote time 2026-10-08 08:44:52 · For reference only, not investment advice and not tailored to your situation.